No Data
Glaxosmithkline (GSK.US) cancer drug Blenrep significantly reduces the risk of death and is expected to regain regulatory approval.
Glaxosmithkline (GSK.US) stated that its blood cancer drug significantly reduced the risk of death in cancer patients when used in combination with another cancer treatment drug.
GlaxoSmithKline To Go Ex-Dividend On November 15th, 2024 With 0.38905 USD Dividend Per Share
November 13th (Eastern Time) - $GlaxoSmithKline(GSK.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.38905 USD dividend per share on
GSK Highlights Key Data From Hepatology Portfolio at the AASLD's The Liver Meeting 2024, Emphasising Patient Impact in Areas of High Unmet Need
GSK Gets Health Canada Approval for Blood Cancer Treatment Ojjaara
Top Midday Stories: Tyson Foods Reports Q4 EPS, Revenue Beats; DOJ Reportedly Moving to Block UnitedHealth's Amedisys Acquisition
GSK, Drax, Centrica; What Brokers Said Today